CHMP recommends EU approval of Roche's Subcutaneous Herceptin for HER2 positive breast cancer

- New injectable administration takes two to five minutes, rather than 30 to 90 minutes with the current intravenous form, potentially saving both healthcare resources and patients' time - Herceptin® is a personalised medicine used to treat more than 80,000 HER2-positive breast cancer patients in Europe each year Roche (SIX: RO, ROG; OTCQX: RHHBY) is pleased to announce that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has today recommended EU approval of a subcutaneous formulation of Herceptin® (trastuzumab) for the treatment of patients with HER2-positive breast cancer. Since Herceptin’s first approval in 1998 this targeted medicine has been used to treat more than 1.3 million patients worldwide.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news